Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States

INTRODUCTION: Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and has been evaluated in the PIONEER clinical trial program. These trials assessed the proportions of patients achieving single and composite endpoints, enc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Barnaby, Hansen, Brian B., Ericsson, Åsa, Kallenbach, Klaus, Ali, Sarah N., Dang-Tan, Tam, Malkin, Samuel J. P., Valentine, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860465/
https://www.ncbi.nlm.nih.gov/pubmed/31650514
http://dx.doi.org/10.1007/s12325-019-01125-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860465/
https://www.ncbi.nlm.nih.gov/pubmed/31650514
http://dx.doi.org/10.1007/s12325-019-01125-y

Ejemplares similares